Ginkgo Bioworks Holdings Financials - Benzinga

Ginkgo Bioworks Holdings Inc

DNANYSE

Trade with Public

Trade with Public

$7.79

-0.71-8.29%

Last update: Aug 7, 2:54 PM

Earnings: Q2 2026 Earnings were released on Wed Aug 5th, after the market close

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Ginkgo Bioworks Holdings Financials

Ginkgo Bioworks Holdings (DNA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ginkgo Bioworks Holdings Q1 EPS $(1.39) Misses $(1.34) Estimate, Sales $19.474M Miss $41.520M Estimate

Benzinga Newsdesk

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks stock drops after earnings miss, lower sales, and shift to autonomous labs and robotics focus.

Vandana Singh

PRO
Ginkgo Bioworks Holdings Q4 EPS $(1.41) Misses $(1.36) Estimate, Sales $33.318M Miss $37.617M Estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.36) by 3.68 percent. This is a 29.5 percent increase over losses of $(2.00) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

Insights into Ginkgo Bioworks Holdings's Upcoming Earnings

Benzinga Insights

Ginkgo Bioworks Stock Plummets Following Q3 Estimates Miss, Reaffirms FY2025 Outlook Below Consensus

Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial results.

Evette Mitkov